Insights - Eloxx (ELOX) shared monotherapy data from their Phase 2 in cystic fibrosis this morning. The data that was reported was not bad, but it left investors wanting … Continue Reading
Premium: Read NowInsights - Medicenna (MDNA) reported a business update late last week. Biomarker data continues to be on schedule for end of year 2021 and initial efficacy data … Continue Reading
Premium: Read NowInsights - Eloxx (ELOX) reported Q3 business update last week which caused the stock to trade lower, presumably because combination data was pushed back from Q1 2022 … Continue Reading
Premium: Read NowInsights - Affimed (AFMD) announced a few updates this morning with ASH nearing. Overall, little substance was shared, which was disappointing as we were expecting AFM13+NK data … Continue Reading
Premium: Read NowInsights - Novavax continues to face regulatory hurdles with their COVID vaccine, and it has been reflected in the company’s stock price. Lack of execution has outweighed … Continue Reading
Premium: Read NowInsights - Biotech (XBI) is back under $125 after a small September rally. On biotech weakness, we’re looking to buy companies on our watchlist or add to … Continue Reading
Premium: Read NowInsights - Affimed (AFMD) released Q2 2021 business update today and it was mixed. AFM13 + MD Anderson collaboration in blood cancers seems to be progressing well, with data … Continue Reading
Premium: Read Now
